case_images: PMC5926496_01
case_images: Clinical parameters during treatment of HS with secukinumab. HSS: Hidradenitis Suppurativa Score; DLQI: Dermatology Life Quality Index; VAS: visual analogue scale; IHS4: International Hidradenitis Suppurativa Severity Score System.
case_images: CRIDM2018-8685136.001.jpg
case_images: PMC5926496_01_CRIDM2018-8685136.001.jpg
case_images: fig1
case_images: After six months of treatment with secukinumab, the patient showed remarkable symptom relief with a reduction in DLQI to 5, HSS to 19, VAS to 7, and IHS4 to 1 (Figure 1).
case_images: Patient photos of the axillary region and the gluteal and genitofemoral region 6 months after treatment with secukinumab showing clearance of most inflammatory lesions.
case_images: CRIDM2018-8685136.002.jpg
case_images: PMC5926496_01_CRIDM2018-8685136.002.jpg
case_images: fig2
case_images: Patient photos 6 months after treatment with secukinumab showed clearance of most inflammatory lesions (Figure 2).